Obstructive Sleep Apnea – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of obstructive sleep apnea (OSA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of OSA for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s OSA forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with OSA?
  • How will demographic trends such as population aging and improving life expectancy affect the epidemiology of OSA over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as a part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 12 OSA patient populations as follows:

  • Total prevalent cases.
  • Total prevalent cases by severity.
    • Total prevalent cases of mild OSA.
    • Total prevalent cases of moderate OSA.
    • Total prevalent cases of severe OSA.
  • Total prevalent cases by comorbidity.
    • Total prevalent cases with comorbid stroke.
    • Total prevalent cases with chronic heart failure.
    • Total prevalent cases with comorbid atrial fibrillation.
    • Total prevalent cases with comorbid asthma.
    • Total prevalent cases with comorbid obesity.
    • Total prevalent cases with no comorbid obesity.
  • Diagnosed prevalent cases.

Note: Coverage may vary by country.

launch Related Market Assessment Reports